Radiofrequency ablation and related ultrasound‐guided ablation technologies for treatment of benign and malignant thyroid disease: An international multidisciplinary …

LA Orloff, JE Noel, BC Stack Jr, MD Russell… - Head & …, 2022 - Wiley Online Library
Background The use of ultrasound‐guided ablation procedures to treat both benign and
malignant thyroid conditions is gaining increasing interest. This document has been …

High-voltage electrical pulses in oncology: irreversible electroporation, electrochemotherapy, gene electrotransfer, electrofusion, and electroimmunotherapy

B Geboers, HJ Scheffer, PM Graybill, AH Ruarus… - Radiology, 2020 - pubs.rsna.org
This review summarizes the use of high-voltage electrical pulses (HVEPs) in clinical
oncology to treat solid tumors with irreversible electroporation (IRE) and …

Guidelines for the diagnosis and treatment of primary liver cancer (2022 edition)

J Zhou, H Sun, Z Wang, W Cong, M Zeng, W Zhou… - Liver cancer, 2023 - karger.com
Background: Primary liver cancer, of which around 75–85% is hepatocellular carcinoma in
China, is the fourth most common malignancy and the second leading cause of tumor …

[HTML][HTML] Guidelines for the diagnosis and treatment of hepatocellular carcinoma (2019 edition)

J Zhou, H Sun, Z Wang, W Cong, J Wang, M Zeng… - Liver cancer, 2020 - karger.com
Background: Primary liver cancer, around 90% are hepatocellular carcinoma in China, is the
fourth most common malignancy and the second leading cause of tumor-related death …

First-in-man histotripsy of hepatic tumors: the THERESA trial, a feasibility study

J Vidal-Jove, X Serres, E Vlaisavljevich… - International Journal …, 2022 - Taylor & Francis
Rationale Current hepatic locoregional therapies are limited in terms of effectiveness and
toxicities. Given promising pre-clinical results, a first in-human trial was designed to assess …

Surgery versus radiofrequency ablation for small hepatocellular carcinoma: a randomized controlled trial (SURF trial)

T Takayama, K Hasegawa, N Izumi, M Kudo… - Liver cancer, 2022 - karger.com
Introduction: It remains unclear which surgery or radiofrequency ablation (RFA) is the more
effective treatment for small hepatocellular carcinoma (HCC). We aimed to compare survival …

[HTML][HTML] Standard for diagnosis and treatment of primary liver cancer (2022 edition)

General Office of National Health Commission - 临床肝胆病杂志, 2022 - lcgdbzz.com
Standard for diagnosis and treatment of primary liver cancer (2022 edition) 中文|English ISSN
1001-5256 (Print) ISSN 2097-3497 (Online) CN 22-1108/R Home About Journal 1.Journal …

Local treatment of unresectable colorectal liver metastases: results of a randomized phase II trial

T Ruers, F Van Coevorden, CJA Punt… - JNCI: Journal of the …, 2017 - academic.oup.com
Background Tumor ablation is often employed for unresectable colorectal liver metastases.
However, no survival benefit hasever been demonstrated in prospective randomized …

Percutaneous treatment of hepatocellular carcinoma: state of the art and innovations

JC Nault, O Sutter, P Nahon, N Ganne-Carrié… - Journal of …, 2018 - Elsevier
Percutaneous treatment of hepatocellular carcinoma (HCC) encompasses a vast range of
techniques, including monopolar radiofrequency ablation (RFA), multibipolar RFA …

Consensus guidelines for the definition of time-to-event end points in image-guided tumor ablation: results of the SIO and DATECAN initiative

RS Puijk, M Ahmed, A Adam, Y Arai, R Arellano… - Radiology, 2021 - pubs.rsna.org
There is currently no consensus regarding preferred clinical outcome measures following
image-guided tumor ablation or clear definitions of oncologic end points. This consensus …